Adicet reports first quarter 2024 financial results and provides business updates

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended march 31, 2024. “we are poised for a transformational year in 2024 as we advance our gamma delta t cell platform in autoimmune diseases and prepare to initiate a phase 1 study evaluating o.
ACET Ratings Summary
ACET Quant Ranking